Lithium Ion

Lithium Ion

SCHEMBL2414962

Cn1cc(-c2cc(Oc3cc(F)c(NC(=O)C4(C(=O)[O-])CC4)cc3F)ccn2)cn1.[Li+]

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 18/20 0.58
▸ AXL P30530 1/20 0.55
▸ PDGFRA P16234 14/20 0.52
▸ PDGFRB P09619 8/20 0.52
▸ MET P08581 5/20 0.52
▸ FLT3 P36888 4/20 0.52
▸ KDR P35968 3/20 0.49
▸ NTRK1 P04629 1/20 0.49
▸ TEK Q02763 1/20 0.49
▸ NTRK3 Q16288 1/20 0.49
▸ NTRK2 Q16620 1/20 0.49
▸ KIT P10721 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12852944 0.92 CSF1R (0.59) CSF1RAXLPDGFRAPDGFRBMET
SCHEMBL3493281 0.91 CSF1R (0.59) CSF1RAXLPDGFRAPDGFRBMET
SCHEMBL2411319 0.91 CSF1R (0.59) CSF1RAXLPDGFRAPDGFRBMET
SCHEMBL29883490 0.89 CSF1R (0.57) CSF1RAXLPDGFRAPDGFRBMET
SCHEMBL2411263 0.89 MET (0.64) CSF1RAXLPDGFRAPDGFRBMET
SCHEMBL2450218 0.89 CSF1R (0.57) CSF1RAXLPDGFRAPDGFRBMET
Hydrochloric Acid SCHEMBL2452300 0.88 CSF1R (0.58) CSF1RAXLPDGFRAPDGFRBMET
SCHEMBL14806723 0.86 CSF1R (0.59) CSF1RAXLPDGFRAPDGFRBMET
SCHEMBL2439504 0.83 CSF1R (0.61) CSF1RAXLPDGFRAPDGFRBMET
SCHEMBL2415429 0.82 MET (0.56) CSF1RAXLPDGFRAPDGFRBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2365752-B1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2014-09-24 — — EP disclosed
US-8486951-B2 Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2013-07-16 — — US disclosed
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-03-28 — — US disclosed
US-8278331-B2 N-acyl ureas exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2012-10-02 — — US disclosed
EP-2365752-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, Llc (US) 2011-09-21 — — EP disclosed
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2010-05-13 — — US disclosed
WO-2010051373-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB CSF1R 14/4885AXL 439/4885PDGFRA 2/4885
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB CSF1R 9/4885AXL 441/4885PDGFRA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback